Travere Therapeutics's top three insider shareholders as of May 14, 2026 are Eric M Dube (Chief Executive Officer, 432.89K shares), Steve Aselage (Chief Executive Officer, 146.92K shares), Peter Heerma (Chief Commercial Officer, 138.61K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Eric M Dube | Chief Executive Officer | 432,886 | 0 | 15 Apr, 2026 |
| Steve Aselage | Chief Executive Officer | 146,919 | 0 | 12 May, 2022 |
| Peter Heerma | Chief Commercial Officer | 138,608 | 0 | 15 Apr, 2026 |
| Christopher R. Cline | Chief Financial Officer | 116,899 | 0 | 15 Apr, 2026 |
| William E. Rote | Chief Research Officer | 113,987 | 0 | 23 Apr, 2026 |
| Jula Inrig | Chief Medical Officer | 111,473 | 0 | 15 Apr, 2026 |
| Elizabeth E Reed | Chief Legal Officer And Gc | 105,211 | 0 | 15 Apr, 2026 |
| Jeffrey A Meckler | - | 87,500 | 0 | 16 May, 2025 |
| Gary A Lyons | - | 57,500 | 0 | 16 Apr, 2026 |
| Timothy Coughlin | - | 55,500 | 0 | 03 Nov, 2025 |
| Noah L. Rosenberg | Chief Medical Officer | 47,614 | 0 | 17 Aug, 2021 |
| Sandra Calvin | Svp, Chief Accounting Officer | 42,353 | 0 | 16 Apr, 2026 |
| Roy D. Baynes | - | 37,500 | 0 | 16 Apr, 2026 |
| Laura Clague | Chief Financial Officer | 35,655 | 0 | 12 May, 2022 |
| John A Orwin | - | 35,375 | 0 | 16 May, 2025 |
| Ron Squarer | - | 35,375 | 0 | 16 May, 2025 |
| Sandra Poole | - | 30,000 | 0 | 16 May, 2025 |
| Suzanne Louise Bruhn | - | 28,750 | 0 | 16 May, 2025 |
| Brinkley Ruth Williams | - | 25,750 | 0 | 16 May, 2025 |
| Steve Aselage | - | 0 | 19,500 | 03 Nov, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 22 Apr, 2026 | William E. Rote | Common Stock | D | 9,100 | $39.09 | 113,987 | D | S |
| 22 Apr, 2026 | William E. Rote | Common Stock | D | 9,100 | $39.09 | 113,987 | D | S |
| 22 Apr, 2026 | William E. Rote | Common Stock | D | 9,100 | $39.09 | 113,987 | D | S |
| 22 Apr, 2026 | William E. Rote | Common Stock | D | 9,100 | $39.09 | 113,987 | D | S |
| 22 Apr, 2026 | William E. Rote | Common Stock | D | 9,100 | $39.09 | 113,987 | D | S |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | A | 2,500 | $22.40 | 51,580 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 8,000 | $17.94 | 45,500 | D | M |
| 14 Apr, 2026 | Gary A Lyons | Common Stock | A | 8,000 | $16.33 | 65,500 | D | M |
| 14 Apr, 2026 | Gary A Lyons | Common Stock | D | 8,000 | $41.07 | 57,500 | D | S |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | A | 6,250 | $8.93 | 57,830 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 9,000 | $15.43 | 54,500 | D | M |
| 14 Apr, 2026 | Gary A Lyons | Stock option (right to buy) | A | 8,000 | $0.00 | 0 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | A | 6,500 | $20.46 | 64,330 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 4,500 | $18.27 | 59,000 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Common Stock | D | 21,977 | $41.07 | 42,353 | D | S |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 4,500 | $21.38 | 63,500 | D | M |
| 14 Apr, 2026 | Sandra Calvin | Employee stock option (right to buy) | D | 2,500 | $0.00 | 5,000 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | A | 6,750 | $17.11 | 70,250 | D | M |
| 14 Apr, 2026 | Roy D. Baynes | Common Stock | D | 26,000 | $41.07 | 44,250 | D | S |
| 14 Apr, 2026 | Sandra Calvin | Employee stock option (right to buy) | D | 6,250 | $0.00 | 12,500 | D | M |